Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioLineRx ADS Representing 15 Ord Shs BLRX

Healthcare Biotechnology
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform ,... see more

Recent & Breaking News (NDAQ:BLRX)

BioLineRx Reports Publication in Peer Review Journal of Results from Previous Phase 1/2 Trial for BCM (BL-1040), a Novel Medical Device for Prevention of Cardiac Remodeling Following Acute Myocardial Infarction

Business Wire October 31, 2014

BioLineRx Presents Positive Preclinical Results in Treatment for AML Patients with FLT3 Mutations

Business Wire September 17, 2014

BioLineRx Doses First Patient for BL-8040's Second Indication as Novel Stem Cell Mobilization Treatment

Business Wire September 3, 2014

BioLineRx to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York

Business Wire September 2, 2014

BioLineRx Receives Notice of Allowance for US Patent on BL-7010 Covering Use of Novel Polymer in Prevention of Gluten Toxicity

Business Wire August 21, 2014

Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014

Business Wire August 11, 2014

BioLineRx Reports Second Quarter 2014 Financial Results

Business Wire August 6, 2014

BioLineRx to Report Second Quarter 2014 Results on August 6, 2014

Business Wire July 30, 2014

BioLineRx Announces Results from Phase 1/2 Study for Celiac Treatment

Business Wire July 16, 2014

BioLineRx In-Licenses Novel Compound for Treatment of Neuropathic Pain

Business Wire June 23, 2014

BioLineRx Receives Approval to Commence Phase 1 Trial for Novel Stem Cell Mobilization Treatment

Business Wire June 16, 2014

BioLineRx Receives Notice of Allowance for US Patent Covering Novel Treatment for Celiac Disease

Business Wire June 11, 2014

BioLineRx Enters into Share Purchase Agreement with Lincoln Park Capital

Business Wire May 30, 2014

BioLineRx Reports First Quarter 2014 Financial Results

Business Wire May 20, 2014

BioLineRx to Report First Quarter 2014 Results on May 20, 2014

Business Wire May 15, 2014

BioLineRx Announces Investigator-Initiated Study for Novel Chronic Myeloid Leukemia Treatment

Business Wire April 10, 2014

BioLineRx Reports Year End 2013 Financial Results

Business Wire March 17, 2014

BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 in Immunotherapy

Business Wire March 14, 2014

BioLineRx to Report Fourth Quarter and Year End 2013 Results on March 17, 2014

Business Wire March 11, 2014

BioLineRx Completes Dose Escalation Stage of Phase 1/2 Study for Novel Celiac Treatment

Business Wire March 10, 2014